Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

1. Trends in utilization of proton pump inhibitors in British Columbia

Trends in utilization of proton pump inhibitors in British Columbia Trends in utilization of proton pump inhibitors in British Columbia February - March 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 118 T he first three Therapeutics Letters focused on com - plaints related (...) to the upper gastrointestinal tract, a common presentation to the primary care physi- cian. 1-3 These Letters reviewed evidence about H 2 -block- ers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first proton pump inhibitor (PPI) on the Canadian market. By 1994 there was already concern that long-term proton pump inhibition could be problem- atic. Since

2019 Therapeutics Letter

2. Proton pump inhibitors: increased mortality

Proton pump inhibitors: increased mortality Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased mortality'', 1 January 2019 {1} {1} {1} | | > > > Proton pump inhibitors: increased mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased mortality FEATURED REVIEW Proton pump inhibitors (PPIs (...) ) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term. Full review (3 pages) available for download by subscribers. Abstract Proton pump inhibitors (PPIs) are widely used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. They provoke few severe adverse effects in the short term, but this is not the case in the long term (infections, fractures

2019 Prescrire

3. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 1 Editorial Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor T reatment (...) and Gastric Cancer after Helicobacter pylori Eradication A recent paper by Cheung et al. (1) reported that long-term use of proton pump inhibitors (PPIs) was associated with an increased risk of gastric cancer “even after” Helicobacter pylori (H. pylori) eradication. This has created significant concerns among physicians and patients (2). The Canadian Association of Gastroenterology (CAG) has serious reservations about the validity of this study and, hence, considers it important to provide guidance

2019 Canadian Association of Gastroenterology

4. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis

Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

5. Advantages and disadvantages of proton pump inhibitor use: an umbrella review of systematic reviews and meta-analyses

Advantages and disadvantages of proton pump inhibitor use: an umbrella review of systematic reviews and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

6. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. (PubMed)

Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Anticoagulant choice and proton pump inhibitor (PPI) cotherapy could affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment.To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants with and without PPI

2018 JAMA

7. Core IM: 5 pearls on proton pump inhibitors

Core IM: 5 pearls on proton pump inhibitors Core IM: 5 Pearls on PPIs – Clinical Correlations Search Core IM: 5 Pearls on PPIs August 29, 2018 15 min read Podcast: | Subscribe: | By Cary Blum MD, Marty Fried MD and Shreya P. Trivedi MD || Illustration by Michael Shen MD. Quiz yourself on the 5 Pearls we will be covering: What are associated adverse effects for patients are on long-term PPIs? (2:02) What are some strategies to get your patient off PPIs? (10:57) How do histamine-2 (H2) receptor (...) have a great graphic of the physiology that might be helpful to follow along with on any of our social media C: Great. So remember that gastric acid is secreted by what cells? M: Umm… Stomach cells? C: Ummm, yes… but more specifically [pause for beat] parietal cells [M: ahhhhh]. They have the hydrogen-potassium ATPase – otherwise known as… S: the proton pump! C: That’s right! The infamous proton pump – purveyor of agida, head honcho of heartburn, the regal ruler of the reflux regime, the- you guys

2018 Clinical Correlations

8. Proton pump inhibitors

Proton pump inhibitors Top results for proton pump inhibitors - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for proton pump inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

9. Deprescribing Proton Pump Inhibitors

Deprescribing Proton Pump Inhibitors Deprescribing Proton Pump Inhibitors March - April 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 111 T he first PPI was approved in Canada in 1988. Pronounced and durable reduction of stomach acid production made omeprazole a “blockbuster (...) Inhibitors. Therapeutics Letter. 2016 (Mar-Apr); 99:1-2. 10. Gomm W , von Holt K, Thom F et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6. DOI:10.1001/jamaneurol.2015.4791 11. Filion KB, Chateau D, Targownik LE et al. Proton pump inhibitors and the risk of hospitalization for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4):552-558. DOI:10.1136/gutjnl-2013-304738 12

2018 Therapeutics Letter

10. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults

Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults To estimate associations between long-term use of proton pump inhibitors (PPIs) and pneumonia incidence in older adults in primary care.Longitudinal analyses of electronic medical records.England PARTICIPANTS: Individuals aged 60 and older in primary care receiving PPIs for 1 year or longer (N=75,050) and age- and sex-matched controls (N=75,050).Net hazard ratios for pneumonia incidence in Year 2

Full Text available with Trip Pro

2018 EvidenceUpdates

11. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014)

No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) Proton pump inhibitors (PPIs) are commonly used medications. Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-users. We evaluated MI risk associated with PPIs compared with histamine-2 receptor antagonists (H2RAs) in privately insured adults in the United States.Using administrative

2018 EvidenceUpdates

12. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis

Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis Pharmacokinetic and prior studies on thienopyridine and proton pump inhibitors (PPI) coadministration provide conflicting data for cardiovascular outcomes, whereas there is no established evidence on the association of concomitant use of PPI and thienopyridines with adverse cerebrovascular outcomes.We conducted a systematic review and meta-analysis of randomized controlled trials

Full Text available with Trip Pro

2018 EvidenceUpdates

13. Proton Pump Inhibitors: Are They a Real Threat to the Patient? (PubMed)

Proton Pump Inhibitors: Are They a Real Threat to the Patient? Proton pump inhibitors are among the most frequently prescribed drugs in the world and are generally considered safe. However, there is growing concern regarding their safety.A nonsystematic review of the current literature was performed regarding proton pump inhibitors and their adverse effects. Proton pump inhibitors seem to be associated with fundic gland polyp development (without clinical relevance) and Clostridium difficile (...) infection. Also, in cirrhotic patients, their prescription should be carefully reviewed. Regarding their association with other enteric infections, micronutrient deficiency, dementia, and chronic kidney disease, current evidence is still of low quality, and further studies are needed.Considering the current evidence, most patients with a clear clinical indication for proton pump inhibitor treatment should probably benefit from the maintenance of their treatment without significant adverse effects

Full Text available with Trip Pro

2018 GE Portuguese journal of gastroenterology

14. A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. (PubMed)

A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME). This study aimed to investigate whether OME can be effectively treated with a proton pump inhibitor (PPI), therefore implicating GER as a causative factor of OME.A PPI or placebo was randomly administered to enrolled subjects for 4-8 weeks. To monitor effusion status, subjects underwent monthly pneumatic

Full Text available with Trip Pro

2018 The journal of international advanced otology

15. Pneumonia caused by proton pump inhibitors (PPI)

Pneumonia caused by proton pump inhibitors (PPI) MED CHECK - TIP December 2017 / Vol.3 No.9 · Page 27 -The Informed Prescriber C N o 9 M ED HECK D e ce m b e r 2 0 1 7 WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia, Sleep Duration, Harm of hypnotics PPI causes Pneumonia Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than (...) benefit: Review Insomnia, Optimal Sleep Duration and Harm of Sleeping pills Pneumonia caused by proton pump inhibitors (PPI) (1) meta-analysis (2) Critical appraisal of a study CONTENTS (December 2017, Vol. 3, No. 9 ) 28 29 34 36 40 42 Volume 3 Page 28 · MED CHECK - TIP December 2017/ Vol.3 No.9 WHO downgrades Tamiflu after reviewing evidence WHO (World Health Organization) reviews their model list of essential medicines every two years. In the revision launched in June 2017, oseltamivir (Tamiflu

2018 Med Check - The Informed Prescriber

16. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.This study was based on a territory-wide health database of Hong Kong. We identified adults who

Full Text available with Trip Pro

2017 EvidenceUpdates

17. Proton pump inhibitors for functional dyspepsia. (PubMed)

Proton pump inhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following

Full Text available with Trip Pro

2017 Cochrane

18. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients (PubMed)

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored.We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study

Full Text available with Trip Pro

2017 Kidney international reports

19. Are higher doses of proton pump inhibitors better in acute peptic bleeding?

Are higher doses of proton pump inhibitors better in acute peptic bleeding? Although there is broad consensus about the benefits of proton pump inhibitors in acute upper peptic bleeding, there is still controversy over their optimal dosing. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified six systematic reviews including 27 randomized trials addressing this question. We combined the evidence using meta-analysis and generated a summary of findings (...) table following the GRADE approach. We concluded high-dose proton pump inhibitors probably result in little or no difference in re-bleeding rate or mortality. The risk/benefit and cost/benefit balance probably favor use of low-doses.

Full Text available with Trip Pro

2017 Medwave

20. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard

2017 EvidenceUpdates